Is there a rationale for heparin use among severe COVID-19 patients?

Is there a rationale for heparin use among severe COVID-19 patients?

Bibliographic Details
Main Author:	Felicio Savioli
Format:	Article
Language:	English
Published:	Instituto Israelita de Ensino e Pesquisa Albert Einstein
Series:	Einstein (São Paulo)
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082020000100104&lng=en&tlng=en

Similar Items

Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection
by: Harry N. Magnani MB, BS, MSc, PhD
Published: (2021-02-01)

Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence
by: Frank M. P. van Haren, et al.
Published: (2020-07-01)

Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO
by: Alexander S. Streng, et al.
Published: (2020-10-01)

Heparin-Induced Thrombocytopenia in COVID-19
by: Prasanth Lingamaneni MD, et al.
Published: (2020-07-01)

Heparin-induced thrombocytopenia and COVID-19
by: Michelangelo Sartori, et al.
Published: (2021-03-01)

Heparin binding protein in severe COVID-19-A prospective observational cohort study.
by: Lisa Mellhammar, et al.
Published: (2021-01-01)

Spontaneous and severe haematomas in patients with COVID-19 on low-molecular-weight heparin for paroxysmal atrial fibrillation
by: Maria Mazzitelli, et al.
Published: (2020-06-01)

Heparin-binding protein levels correlate with aggravation and multiorgan damage in severe COVID-19
by: Mingshan Xue, et al.
Published: (2021-02-01)

The challenges of diagnosing heparin‐induced thrombocytopenia in patients with COVID‐19
by: Jori E. May, et al.
Published: (2020-08-01)

Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection
by: Kadir Canoglu, et al.
Published: (2020-12-01)

Response to The challenges of diagnosing heparin‐induced thrombocytopenia in patients with COVID‐19
by: Richard R. Riker, et al.
Published: (2020-08-01)

Spontaneous Hematomas in COVID-19 Patients on Low-Molecular-Weight Heparin
by: Hitesh Taleja, et al.
Published: (2021-09-01)

Rationale for targeting complement in COVID‐19
by: Anastasia Polycarpou, et al.
Published: (2020-08-01)

The Rationale for Potential Pharmacotherapy of COVID-19
by: Maha Saber-Ayad, et al.
Published: (2020-05-01)

Exploring the rationale for thermotherapy in COVID-19
by: Javier Mancilla-Galindo, et al.
Published: (2021-01-01)

Copper-Heparin Inhalation Therapy To Repair Emphysema: A Scientific Rationale
by: Janssen R, et al.
Published: (2019-11-01)

Heparin Therapy Improving Hypoxia in COVID-19 Patients – A Case Series
by: Elnara Marcia Negri, et al.
Published: (2020-10-01)

Nebulized Heparin for Post-COVID-19-Related Hypoxia
by: Mehmet Hursitoglu, et al.
Published: (2021-07-01)

COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
by: Alessandra F. Perna, et al.
Published: (2020-05-01)

The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19
by: Heloísa Antoniella Braz-de-Melo, et al.
Published: (2021-04-01)

Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
by: Baranca Buijsers, et al.
Published: (2020-09-01)

Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients
by: Pasquale Paolisso, et al.
Published: (2020-08-01)

Can Heparin-Coated ECMO Cannulas Induce Thrombocytopenia in COVID-19 Patients?
by: Barbara Steinlechner, et al.
Published: (2021-01-01)

Iliopsoas hematoma in patients with COVID-19 on low-molecular-weight heparin treatment
by: Gianluca Sottilotta, et al.
Published: (2021-05-01)

Venous thrombotic events in severe and critically COVID-19 patients despite high dose prophylactic low-molecular-weight heparin
by: Chantal Visser, et al.
Published: (2020-12-01)

Chloroquine for COVID-19: rationale, facts, hopes
by: Andrea Cortegiani, et al.
Published: (2020-05-01)

Iloprost in COVID-19: The Rationale of Therapeutic Benefit
by: Paola Maria Faggioli, et al.
Published: (2021-04-01)

Preventing Thrombohemorrhagic Complications of Heparinized COVID-19 Patients Using Adjunctive Thromboelastography: A Retrospective Study
by: Connor M. Bunch, et al.
Published: (2021-07-01)

The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review
by: Lucia Gozzo, et al.
Published: (2020-08-01)

Management of therapeutic unfractionated heparin in COVID‐19 patients: A retrospective cohort study
by: Lachelle D. Weeks, et al.
Published: (2021-05-01)

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients
by: Christopher J. Rogers, et al.
Published: (2020-05-01)

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
by: A. Cortegiani, et al.
Published: (2021-01-01)

Rationales and uncertainties for aspirin use in COVID-19: a narrative review
by: Hazem A Sayed Ahmed, et al.
Published: (2021-03-01)

Rationale and Criteria for a COVID-19 Model Framework
by: Francesco Messina, et al.
Published: (2021-07-01)

Low molecular weight heparins in COVID-19 patients: beware of augmented renal clearance!
by: Teresa Maria Tomasa-Irriguible, et al.
Published: (2020-06-01)

Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients
by: Giorgio Zauli, et al.
Published: (2020-07-01)

Rationale for azithromycin in COVID-19: an overview of existing evidence
by: Iwein Gyselinck, et al.
Published: (2021-08-01)

COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation
by: Wolfgang Miesbach MD, et al.
Published: (2020-07-01)

Rationale for Mass Masking in Controlling the COVID-19 Pandemic
by: Shing Yau Tam, et al.
Published: (2021-08-01)

A Scientific Rationale for Using Cystic Fibrosis Transmembrane Conductance Regulator Therapeutics in COVID-19 Patients
by: Darcy Lidington, et al.
Published: (2020-11-01)